Source-grounded facts extracted from MapLight Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jonathan Gillis was appointed as interim Chief Financial Officer at MapLight Therapeutics, Inc..
“the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.”
Vishwas Setia departed as Chief Financial Officer at MapLight Therapeutics, Inc..
“Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.”
MapLight Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $60.7 million.
“On May 14, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Troy Cox was appointed as Class I Director at MapLight Therapeutics, Inc..
“The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.”
Martin Babler was appointed as Class I Director at MapLight Therapeutics, Inc..
“The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.”
Jim Trenkle departed as Director at MapLight Therapeutics, Inc..
“On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.”
Robert Malenka departed as Director at MapLight Therapeutics, Inc..
“On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.”
MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.
“For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.”
MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.
“Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.”
MapLight Therapeutics, Inc.: Amended and restated bylaws adopted effective upon IPO closing (effective 2025-10-28).
“Effective as of October 28, 2025, the Company adopted amended and restated bylaws (the “ Restated Bylaws ”) in connection with the closing of the IPO.”
MapLight Therapeutics, Inc.: Amended and restated certificate of incorporation filed in connection with IPO closing (effective 2025-10-28).
“In connection with the closing of the initial public offering (“ IPO ”) of shares of common stock, par value $0.0001 per share (“ Common Stock ”), of MapLight Therapeutics, Inc. (the “ Company ”), on October 28, 2025, the Company filed an amended and restated certificate of incorporation (the “ Restated Certificate ”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.